StockData
Biodexa Pharmaceuticals Plc logo

Biodexa Pharmaceuticals Plc (BDRX) stock

BDRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 1/30
$2.04−0.10 (-4.89%)

Close on Nov 18, 2026Market cap $4.60MP/E –Yield –

Biodexa Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was -£5.59M. The highest annual figure on record is -£5.59M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-£5.59M–
FY2024Dec 31, 2024-£12.27M–
FY2023Dec 31, 2023-£6.85M–
FY2022Dec 31, 2022-£7.11M–
FY2021Dec 31, 2021-£6.33M–
FY2020Dec 31, 2020-£9.51M–
FY2019Dec 31, 2019-£6.80M–
FY2018Dec 31, 2018-£13.69M–
FY2017Dec 31, 2017-£13.66M–
FY2016Dec 31, 2016-£14.43M–
FY2015Dec 31, 2015-£13.34M–

More Biodexa Pharmaceuticals figures

See a number that looks wrong?